Cargando…

Silicone Implant Shells Increase the Rate of Proliferation of Alk- but Not Alk+ Lymphoma Cells in an Engineered Biomimetic Breast Microenvironment

Detalles Bibliográficos
Autores principales:	Premaratne, Ishani D., Wright, Matthew A., Gadjiko, Mariam, Dong, Xue, Samadi, Arash, Lara, Daniel O., Berri, Nabih, Ginter, Paula S., Inghirami, Giorgio, Brown, Kristy A., Spector, Jason A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Research & Technology Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553431/ http://dx.doi.org/10.1097/01.GOX.0000721032.97725.62

Ejemplares similares

4485 Silicone Implant Shells Increase the Rate of Proliferation of Patient-Derived BIA-ALCL Cells but Not Primary T Cells in an Engineered Biomimetic Breast Platform
por: Premaratne, Ishani, et al.
Publicado: (2020)

Abstract 125: Silicone Implant Shells Increase The Rate Of Proliferation Of Patient-derived BIA-ALCL Cells But Not Primary T Cells In An Engineered Biomimetic Patient-derived Breast Tissue
por: Premaratne, Ishani D., et al.
Publicado: (2020)

6: Creating Tissue Engineered Nipples Using 3d-printed Poly-4-hydroxybutyrate (p4hb) Bioabsorbable Scaffolds Augmented With Autologous Processed Costal Cartilage
por: Dong, Xue, et al.
Publicado: (2021)

Abstract 134: Tissue Engineered Neo-nipples Fabricated From Autologous Costal Cartilage Maintain Projection And Biomechanical Properties Of The Native Human Nipple
por: Premaratne, Ishani D., et al.
Publicado: (2020)

Exploring the Effect of Implant Shell on Patient-derived Breast Implant–associated Anaplastic Large Cell Lymphoma Cells in Ex Vivo Biomimetic Breast Tissue
por: Wright, Matthew A., et al.
Publicado: (2019)

The heterogeneous landscape of ALK negative ALCL
por: Mereu, Elisabetta, et al.
Publicado: (2017)

Abstract 11: A Novel Tissue Engineered Three-Dimensional Biomimetic Platform for In Vitro Study of BIA-ALCL
por: Wright, Matthew A., et al.
Publicado: (2019)

ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma
por: Tabbó, Fabrizio, et al.
Publicado: (2012)

Optimizing Human Elastic Cartilage Engineering using Mesenchymal Stem Cell Chaperones
por: Dong, Xue, et al.
Publicado: (2021)

Live Imaging Tissue Culture Made Easy: A Novel Device for Perfusion Cell Culture and Live Imaging
por: Bender, Ryan, et al.
Publicado: (2021)

Long Term Maintenance of Nipple Projection Using 3D-printed Poly-4-Hydroxybutyrate Bioabsorbable Scaffolds Augmented with Autologous Processed Costal Cartilage
por: Dong, Xue, et al.
Publicado: (2021)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

ALK Inhibitors in the Treatment of ALK Positive NSCLC
por: Khan, Muhammad, et al.
Publicado: (2019)

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib
por: Du, Xue, et al.
Publicado: (2018)

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

The role of Alk-1 and Alk-5 in the mechanosensing of chondrocytes
por: Sanz-Ramos, Patricia, et al.
Publicado: (2014)

ALK+ Anaplastic Large Cell Lymphoma (ALCL)-Derived Exosomes Carry ALK Signaling Proteins and Interact with Tumor Microenvironment
por: Chioureas, Dimitrios, et al.
Publicado: (2022)

Abstract 33: Understanding the Role of Adipocytes and the Tumor Microenvironment on Doxorubicin Therapy of Breast Cancer in a Tissue Engineered, Patient Specific, High-throughput Biomimetic Platform
por: Lara, Daniel, et al.
Publicado: (2019)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Topical Alpha-Gal Nanoparticles Enhances Wound Healing in Radiated Tissue
por: Samadi, Arash, et al.
Publicado: (2019)

Peptides derived from the dependence receptor ALK are proapoptotic for ALK-positive tumors
por: Aubry, A, et al.
Publicado: (2015)

Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
por: Duijkers, Floor A. M., et al.
Publicado: (2011)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

Impact of ALK Inhibitors in Patients With ALK-Rearranged Nonlung Solid Tumors
por: Takeyasu, Yuki, et al.
Publicado: (2021)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

A biomimetic pancreatic cancer on-chip reveals endothelial ablation via ALK7 signaling
por: Nguyen, Duc-Huy T., et al.
Publicado: (2019)

Identification of the Wallenda JNKKK as an Alk suppressor reveals increased competitiveness of Alk-expressing cells
por: Wolfstetter, Georg, et al.
Publicado: (2020)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
por: Iannantuono, Giovanni Maria, et al.
Publicado: (2022)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Inhibiting ALK2/ALK3 Signaling to Differentiate and Chemo-Sensitize Medulloblastoma
por: Filipponi, Doria, et al.
Publicado: (2022)

Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancer
por: Lovly, Christine M., et al.
Publicado: (2014)

22. COMPARATIVE EFFICACY OF ALK-INHIBITORS IN ALK INHIBITOR-NAIVE ALK+ LUNG CANCER BRAIN METASTASES: A NETWORK META-ANALYSIS
por: Haddad, Philip, et al.
Publicado: (2020)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0150mf07ocabmchbhcp6imljia